C8895
Clofazimine
≥98% (TLC), powder, antimycobacterial rimonphenazine
동의어(들):
N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine
로그인조직 및 계약 가격 보기
모든 사진(4)
About This Item
실험식(Hill 표기법):
C27H22Cl2N4
CAS Number:
Molecular Weight:
473.40
EC Number:
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:
NACRES:
NA.77
추천 제품
제품명
Clofazimine,
양식
powder
Quality Level
항생제 활성 스펙트럼
mycobacteria
동작 모드
protein synthesis | interferes
주관자
Novartis
SMILES string
CC(C)\N=C1/C=C2N(c3ccc(Cl)cc3)c4ccccc4N=C2C=C1Nc5ccc(Cl)cc5
InChI
1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24+
InChI key
WDQPAMHFFCXSNU-BGABXYSRSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
Clofazimine is a riminophenazine, which is used as an antileprosy drug. It is used to treat multidrug-resistant tuberculosis. Clofazimine prevents neutrophil motility and lymphocyte transformation. It has anti-inflammatory effect, which is used to treat discoid lupus erythematosus. Clofazimine has immunosuppressive property.
애플리케이션
Clofazimine has been used:
- for antimicrobial preparation
- to study its accumulation on macrophages to form crystal-like drug inclusions (CLDIs)
- to model drug-induced hepatic granulomatous inflammation
- to study the in vivo cargo storage capacity of macrophages
특징 및 장점
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
저장 및 안정성
This product is stored at room temperature.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
개인 보호 장비
dust mask type N95 (US), Eyeshields, Gloves
이미 열람한 고객
The Antimicrobial Drugs (2000)
Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis
Lechartier B and Cole ST
Antimicrobial Agents and Chemotherapy, 59(8), 4457-4463 (2015)
Macrophage-mediated clofazimine sequestration is accompanied by a shift in host energy metabolism
Trexel J, et al.
Journal of Pharmaceutical Sciences, 106(4), 1162-1174 (2017)
Sarah Schmidt Grant et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(30), 12147-12152 (2012-07-11)
During Mycobacterium tuberculosis infection, a population of bacteria likely becomes refractory to antibiotic killing in the absence of genotypic resistance, making treatment challenging. We describe an in vitro model capable of yielding a phenotypically antibiotic-tolerant subpopulation of cells, often called
Jakko van Ingen et al.
Antimicrobial agents and chemotherapy, 56(12), 6324-6327 (2012-10-03)
Disease caused by nontuberculous mycobacteria (NTM) is increasing in frequency. The outcome of treatment for NTM lung disease is poor, particularly lung disease caused by Mycobacterium simiae and M. abscessus. Exploring synergy between active available drugs is a sensible way
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.